سابِق|تال

The effect of Biejiajian Pills on regulating the EGFR/MAPK/ERK pathway in MHCC-97H liver cancer cells

  • role： First author第一作者
  • Affiliation：

    The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410007, China

  • Introduction：伍梦思，女，在读博士生，主治医师
WU Mengsi1,  
  • Affiliation：

    The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410007, China

LIU Hua1,  
  • Affiliation：

    School of Integrative Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha 410208, China

TAN Nianhua2,  
  • Affiliation：

    The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410007, China

LI Yaoyao1,  
  • Affiliation：

    The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410007, China

DING Lin1,  
  • Affiliation：

    The 8th Medical Center, Chinese PLA General Hospital, Beijing 100853, China

XIA Yu3,  
  • Affiliation：

    The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410007, China

CHEN Yang1,  
  • role： Corresponding author通信作者
  • Affiliation：

    The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410007, China

  • Email：chenbin0410@qq.com
  • Introduction：Prof. CHEN Bin, Ph.D., Chief Physician, Doctoral Supervisor. The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, No. 95, Shaoshan Middle Road, Yuhua District, Changsha 410007. E-mail: chenbin0410@qq.com
CHEN Bin1*

ملخص

ObjectiveWe aimed to investigate the effects of Biejiajian Pills on MHCC-97H hepatoma cells and whether Biejiajian Pills regulate the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathway through miR-885-5p.MethodsSPF SD rats (n = 10) were randomly divided into the blank group and the Biejiajian Pills (1.1 g/kg) group to prepare blank and Biejiajian Pills-containing serum. MHCC-97H cells in the logarithmic growth phase were divided into the model group, blank serum groups with different concentrations (5%, 10%, 15%, and 20%), the serum containing Biejiajian Pills group, and the blank group without cells. Cell proliferation was detected by the CCK-8 assay, and the optimal intervention time and concentration of drug-containing serum were screened. MHCC-97H cells were divided into the blank control group (no intervention), the Biejiajian Pills-containing serum group (20% Biejiajian Pills-containing serum), the miR-885-5p mimics group (transfected with miR-885-5p mimics), the miR-NC group (transfected with miR-885-5p NC), and the Biejiajian Pills-containing serum + miR-885-5p mimics group (treated with 20% Biejiajian Pills-containing serum and transfected with miR-885-5p mimics). Cells in each group were cultured for 72 hours. A dual luciferase reporter assay was conducted to verify the targeting relationship between miR-885-5p and EGFR. Cell proliferation was detected by the CCK-8 assay, cell migration and invasion abilities were detected by the cell scratch assay and the Transwell invasion assay. Annexin V-APC/PI double staining was performed to detect the apoptosis level, and real-time fluorescence quantitative PCR (RT-qPCR) analysis was conducted to determine the mRNA expression levels of miR-885-5p, EGFR, MEK, and ERK1/2. The expression levels of EGFR, p-EGFR, MEK, p-MEK, ERK1/2, p-ERK1/2, matrix metalloproteinase 1 (MMP1), and CyclinD1 were determined by Western blotting analysis. The subcutaneous tumor model of MHCC-97H hepatoma cells in nude mice was established by subcutaneous injection to observe the inhibitory effect of Biejiajian Pills of different doses(0.55, 1.1, 2.2 g/kg).ResultsThe optimal concentration and intervention time of Biejiajian Pills-containing serum were 20% and 72 hours, respectively. Meanwhile, the dual luciferase reporter assay showed that miR-885-5p could directly target EGFR. No statistical significances between the blank control group and the miR-NC group were observed (P>0.05). Compared with the blank control group, the proliferation rates of MHCC-97H hepatoma cells in the Biejiajian Pills-containing serum group, the miR-885-5p mimics group, and the Biejiajian Pills-containing serum + miR-885-5p mimics group were significantly decreased (P<0.01), and their migration and invasion abilities were significantly decreased (P<0.05, P<0.01). At the same time, the protein expression levels of CyclinD1 and MMP1, which are closely related to cell proliferation and invasion, were significantly downregulated (P<0.05, P<0.01). The proportions of late apoptotic cells and the proportion of total apoptotic cells were significantly increased (P<0.01). In the Biejiajian Pills-containing serum group, the miR-885-5p mimics group, and the Biejiajian Pills-containing serum + miR-885-5p mimics group, miR-885-5p mRNA was significantly upregulated (P<0.01) and EGFR, MEK, and ERK1/2 were significantly downregulated at the mRNA level (P<0.05, P<0.01). EGFR, MEK, and ERK1/2 phosphorylation was inhibited (P<0.01), and the Biejiajian Pills-containing serum + miR-885-5p mimics group showed the best effect (P<0.05, P<0.01). The subcutaneous liver tumor model in nude mice verified that Biejiajian Pills can inhibit tumor growth in a dose-dependent manner.ConclusionBiejiajian Pills can promote apoptosis of MHCC-97H hepatoma cells and inhibit their proliferation, invasion, and migration. The mechanism may be related to the targeted regulation of the EGFR/MAPK/ERK signaling pathway by miR-885-5p.

مفهوم

Biejiajian Pills;miR-885-5p;epidermal growth factor receptor;mitogen-activated protein kinase;MHCC-97H hepatoma cells;nude mice;subcutaneous tumor

References

  1. [1].
    RANKOVIĆ B, HAUPTMAN N. Circulating microRNA panels for detection of liver cancers and liver-metastasizing primary cancers[J]. Int J Mol Sci, 2023, 24(20): 15451.
  2. [2].
    LU X, PALIOGIANNIS P, CALVISI DF, et al. Role of the mammalian target of rapamycin pathway in liver cancer: from molecular genetics to targeted therapies[J].Hepatology, 2021，73(1): 49-61.
  3. [3].
    MOHR R, ÖZDIRIK B, LAMBRECHT J, et al. From liver cirrhosis to cancer: The role of micro-rnas in hepatocarcinogenesis[J]. Int J Mol Sci, 2021, 22(3):1492.
  4. [4].
    HE GN, BAO NR, WANG S, et al. Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1/miR-214-3p/GPX4[J]. Drug Des Devel Ther, 2021, 15:3965-3978.
  5. [5].
    ZHANG X, XU XY, GE GH, et al. miR-498 inhibits the growth and metastasis of liver cancer by targeting ZEB2[J]. Oncol Rep, 2019, 41(3):1638-1648.
  6. [6].
    ZHANG CY, SUN CF, ZHAO YB, et al. Overview of microRNAs as diagnostic and prognostic biomarkers for high-incidence cancers in 2021[J]. Int J Mol Sci, 2022, 23(19): 11389.
  7. [7].
    YIN SS, JIN WK, QIU YL, et al. Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment[J]. J Hematol Oncol, 2022, 15(1): 32.
  8. [8].
    SUN DZ, YE M, JU DW, et al. The effects of gastric cancer interstitial fluid on tumors based on traditional Chinese medicine ‘phlegm’ theory and the investigation on the mechanism through microRNA-21 regulation[J]. J Physiol Pharmacol, 2021, 72(3): 34810290.
  9. [9].
    WANG YP, FU XQ, YIN CL, et al. A traditional Chinese medicine formula inhibits tumor growth in mice and regulates the miR-34b/c-Met/β-catenin pathway[J]. J Ethnopharmacol, 2020, 260: 113065.
  10. [10].
    SI T, HUANG LY, LIANG T, et al. Ruangan Lidan Decoction inhibits the growth and metastasis of liver cancer by downregulating miR-9-5p and upregulating PDK4[J]. Cancer Biol Ther, 2023, 24(1): 2246198.
  11. [11].
    程丹颖，郭朋，孙凤霞，等．恩替卡韦联合鳖甲煎丸治疗慢性乙型肝炎肝纤维化瘀血内阻证的临床疗效及其对中医证候积分的影响[J]. 中华肝脏病杂志，2023, 31(6): 608-613.
  12. [12].
    HUANG JJ, HUANG HN, WANG XJ, et al. Bie Jia Jian pill enhances the amelioration of bone mesenchymal stem cells on hepatocellular carcinoma progression[J]. J Nat Med, 2022, 76(1): 49-58.
  13. [13].
    李明芬，潘爱萍，林英辉，等. 鳖甲煎丸含药血清抑制肝癌细胞的miRNA-mRNA调控机制分析[J]. 中成药，2021, 43(6): 1437-1444.
  14. [14].
    王晓琛. LINC01225促进原发性肝癌发生与发展的机制研究[D]. 南京：南京医科大学，2016.
  15. [15].
    XU F, YAN JJ, GAN Y, et al. miR-885-5p negatively regulates warburg effect by silencing hexokinase 2 in liver cancer[J]. Mol Ther Nucleic Acids, 2019, 18: 308-319.
  16. [16].
    张丽云，范宇，李晓红. miR-885-5p通过靶向CTNNB1抑制胰腺癌细胞增殖、迁移和侵袭[J]. 现代肿瘤医学，2022, 30(17): 3083-3088.
  17. [17].
    钟晓丹，文彬，孙海涛，等. 鳖甲煎丸通过NF-κB信号通路抑制肝癌细胞上皮间质转化的作用机制[J]. 中国实验方剂学杂志，2022, 28(1): 24-32.
  18. [18].
    于笑笑，李曼，马利节，等. 基于AKT信号通路探讨鳖甲煎丸诱导H22肝癌细胞皮下瘤细胞凋亡的作用机制[J]. 中华中医药杂志，2022, 37(8): 4449-4453.
  19. [19].
    孙海涛，文彬，陈冠新，等. 鳖甲煎丸对肝纤维化模型大鼠肝组织中Wnt/β-catenin信号通路相关蛋白及其靶基因表达的影响[J]. 中医杂志，2018, 59(10): 876-881.
  20. [20].
    JIN HJ, SHI YP, LV YY, et al. EGFR activation limits the response of liver cancer to lenvatinib[J]. Nature, 2021, 595(7869): 730-734.
  21. [21].
    CHEN L, GUO P, HE YC, et al. HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway[J]. Cell Death Dis, 2018, 9(5): 513.
  22. [22].
    张传海，桂阳，郭凤林，等. EGFR基因knockdown对肝癌细胞MHCC-97H侵袭迁移能力的影响[J]. 安徽医科大学学报，2017, 52(8): 1133-1137.
  23. [23].
    杨玥玮，程楠，刘丽然，等. 香连化浊方对慢性萎缩性胃炎模型大鼠胃黏膜EGFR/MAPK/ERK信号通路的影响[J]. 中医杂志，2023, 64(14): 1483-1490.
  24. [24].
    WANG CQ, HE Q, YIN YX, et al. Clonorchis sinensis granulin promotes malignant transformation of hepatocyte through EGFR-mediated RAS/MAPK/ERK and PI3K/akt signaling pathways[J]. Front Cell Infect Microbiol, 2021, 11: 734750.
  25. [25].
    LI C, WANG XH, SONG Q. microRNA 885-5p inhibits hepatocellular carcinoma metastasis by repressing AEG1[J]. Onco Targets Ther, 2020, 13: 981-988.
  26. [26].
    许菲. miR-885-5p通过沉默HK2在肝细胞癌糖酵解中的作用研究[D]. 武汉：武汉大学，2020.
  27. [27].
    ZHANG ZH, YIN J, YANG J, et al. miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/β-catenin signaling pathway[J]. Oncotarget, 2016, 7(46): 75038-75051.
  28. [28].
    彭涛. 鳖甲煎丸在肝癌治疗中的临床应用[J]. 中西医结合肝病杂志，2020, 30(6): 481-483.
  29. [29].
    罗倩，苏联军，张林子，等. 基于网络药理学和分子对接探讨鳖甲煎丸抗肝癌的作用机制[J]. 中国中医药图书情报杂志，2023, 47(5): 11-17.
  30. [30].
    SUN JL, CHEN WC, WEN B, et al. Biejiajian pill inhibits carcinogenesis and metastasis via the akt/GSK－3β/snail signaling pathway in hepatocellular carcinoma[J]. Front Pharmacol, 2021, 12(1): 610158.
  31. [31].
    CHEN WC, YANG XM, SUN JL, et al. Biejiajian pill inhibits progression of hepatocellular carcinoma by downregulating PDGFRβ signaling in cancer-associated fibroblasts[J]. J Ethnopharmacol, 2023, 301: 115825.

قراءة النص الكامل

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website